Revenue from operations dropped 9.3% to ₹475.4 crore from ₹524 crore a year ago, the company said in an exchange filing.
Despite weaker sales, Sanofi India’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 12% to ₹134 crore, lifting its operating margin to 28% from 23% a year earlier, supported by cost efficiency measures and a favourable product mix.
The company, a unit of French drugmaker Sanofi SA, has been streamlining its portfolio in India to focus on core therapeutic areas such as diabetes and cardiovascular treatments.Separately, the company’s board approved unaudited results for the quarter ended September 30, 2025, reporting a net profit of ₹760 crore, down from ₹822 crore a year earlier, while revenue fell to ₹4,754 crore from ₹5,240 crore. The board also declared an interim dividend of ₹75 per share for FY25, with November 7 set as the record date.
The company also announced the appointment of Deepak Arora as its Managing Director for a three-year term effective October 27, 2025.
Arora, a pharma veteran with over 30 years of global experience across North America, Europe, the Middle East, and Africa, replaces Rachid Ayari, who stepped down as Interim Managing Director but continues as Whole-time Director and CFO.
Shares of Sanofi India were little changed at ₹4,747.00 after the results announcement. The stock has gained about 22% so far this year, underperforming the Nifty Pharma index, which has fallen around 4.5% in the same period.
First Published: Oct 29, 2025 2:16 PM IS
